BioPharmSignal logoBioPharmSignal

Biotech News

GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures

GRI Bio (GRI)GRI BioCompany update

Issued Claims Protect Distinct Molecular Designs with Broad Therapeutic Potential Across Inflammatory, Fibrotic, and Autoimmune Diseases

LA JOLLA, CA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- <a...

Related news

GRIGRI Bio2026-06-18 13:31 EST

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

GRIGRI Bio2026-08-24 14:05 EST

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

INMBINmune Bio2026-07-01 11:00 EST

INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion

CABACabaletta Bio2026-06-03 11:00 EST

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

ZURAZura Bio2026-08-21 23:57 EST

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SABSSAB Biotherapeutics2026-07-30 12:30 EST

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

SABSSAB Biotherapeutics2026-05-29 12:00 EST

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

View all latest news

GRI Bio

BioRestorative or GRI is a historical small-cap biotech entry tied to biologics and regenerative or related platform work. Its story is best understood as an early-stage development attempt rather than a mature commercial franchise.

Recent company news

GRIGRI Bio2026-08-24 14:05 EST

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

GRIGRI Bio2026-06-18 13:31 EST

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

GRIGRI Bio2026-05-14 13:35 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

GRIGRI Bio2026-05-14 13:35 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

GRIGRI Bio2026-05-14 08:35 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

Stock data

Close
1.65 USD
Market cap
3.56M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States